Scientific aspects of afferent visual dysfunction in neuro-degenerative disease
Geoffrey K Aguirre, MD, PhD
G G G A A A K A A G A K K A K G A
G K A
G G K K K G K
LAB
Scientific aspects of a ff erent visual dysfunction in - - PowerPoint PPT Presentation
Scientific aspects of a ff erent visual dysfunction in neuro-degenerative disease Geo ff rey K Aguirre, MD, PhD K G A A G G G K K A K K LAB K K G A K G G A G A G K A A A GKA is an inventor on U.S. Patent Application
G G G A A A K A A G A K K A K G A
G K A
G G K K K G K
LAB
Melanopsin foreshadowing
Javaid, Fatimah Zara, et al. "Visual and ocular manifestations of Alzheimer’s disease and their use as biomarkers for diagnosis and progression." Frontiers in neurology 7 (2016). Mattis, Joanna, and Amita Sehgal. "Circadian rhythms, sleep, and disorders of aging." Trends in Endocrinology & Metabolism 27.4 (2016): 192-203.
Reviewed in Javaid et al., 2016 Frontiers in Neurology
Watson and Yellot, 2012 JoV; replotted data from Winn et al., 1994 IOVS
20 30 40 50 60 70 80 90 8 6 4 2
Melanopsin foreshadowing
Lerman, Sidney. Radiant energy and the eye. Vol. 1. Macmillan, 1980.
Lerman, Sidney. Radiant energy and the eye. Vol. 1. Macmillan, 1980.
Melanopsin foreshadowing
Goldstein, Lee E., et al. The Lancet 361.9365 (2003): 1258-1265.
Bei, Ling, et al. Experimental eye research 140 (2015): 117-123.
Coppola, Gianluca, et al. PLoS One 10.8 (2015): e0134750.
(although see Lad et al., PLOS One 2018)
Masuzzo, Ambra, et al. Frontiers in Neurology 7 (2016).
et al.., NeuroImage 2011; Morgia et al., Annals Neurology 2016)
Rosenbloom, M. H., et al. Neurology 76.21 (2011): 1789-1796.
At the initial visit 24 months RE LE
a c b
RE LE
Goto, Katsutoshi, et al. Graefe's Archive for Clinical and Experimental Ophthalmology 254.4 (2016): 745-756. Cowey, Alan, et al., Brain 134.7 (2011): 2149-2157.
Ong, Yi-Ting, et al. Neuroscience letters 584 (2015): 12-16.
Multivariable-adjusted estimated mean change in GC-IPL and RNFL thicknesses (95%CI) per standard deviation change in MRI markers. GC-IPL thickness (95%CI) (m)* RNFL thickness (95%CI) (m)*,† Per SD decrease in occipital lobe Grey + white matter volume −1.77 (−6.55, 0.01) −1.87 (−4.44. 0.69) Grey matter volume −1.78 (−3.20, −0.36) −1.72 (−3.79, 0.34) White matter volume 0.07 (−1.68, 1.81) −0.27 (−2.79, 2.25) Per SD decrease in temporal lobe Grey + white matter volume −3.45 (−5.40, −1.49) −2.70 (−2.61, 0.21) Grey matter volume −2.94 (−4.46, −1.41) −2.56 (−4.85, −0.27) White matter volume −0.55 (−2.57, 1.46) 0.14 (−2.76, 3.05) Per SD decrease in frontal lobe Grey + white matter volume 0.05 (−2.67, 2.76) 1.16 (−2.72, 5.03) Grey matter volume −0.34 (−3.20, 1.53) 0.59 (−2.09, 3.26) White matter volume 0.81 (−1.51, 3.14) 0.56 (−2.69, 3.82)
La Morgia, Chiara, et al. Frontiers in Neurology 8 (2017): 162.
La Morgia, Chiara, et al. Annals of neurology 79.1 (2016): 90-109.
Melanopsin time
cones bipolars RGCs
S M Melanopsin L 500 400 600 700 800
Wavelength [nm] Sensitivity
S M Melanopsin L 500 400 600 700 800
Wavelength [nm] Transmittane Sensitivity Lens young
Esquiva, Gema, et al. Frontiers in Aging Neuroscience 9 (2017).
La Morgia, Chiara, et al. Annals of neurology 79.1 (2016): 90-109.
La Morgia, Chiara, et al. Annals of neurology 79.1 (2016): 90-109.
La Morgia, Chiara, et al. Annals of neurology 79.1 (2016): 90-109.
Post-illumination pupil response (PIPR) indirect measure Silent-substitution isolation of melanopsin direct measure
–30 % pupil Δ 13 seconds
Spitschan, Manuel, et al. PNAS 114.46 (2017): 12291-12296
Gamlin PDR, et. al. Vision Res. 2007;47(7):946-954
AV Rukmini, et al. Scientific Reports. 7 (2017): 43832.
| 7:43832 | DOI: 10.1038/srep43832